CD36 and acute myeloid leukemia: Relapsed or refractory AML cells showed increased dependency for survival on fatty acid metabolism [30], and it was shown that simultaneous inhibition of BCL-2 and fatty acid uptake by a CD36 inhibitor decreased OXPHOS and viability in relapsed AML cells [30,98].